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Abstract
Background: The literature reports various treatment methodologies, such as trans-oral laser microsurgery, radiation
therapy, total/partial laryngectomies, and concurrent radiation chemotherapy for patients with early larynx cancer.
However, at the forefront of early glottis treatment is trans-oral laser microsurgery and radiation therapy, likely due to
better functional and survival outcomes. Here we conduct the largest Canadian head-to-head comparison of consecutive
patients treated with either radiation therapy or trans-oral laser microsurgery. Additionally, we compare these two
treatments and their 5-year survival rates post treatment to add to the existing literature.
Methods: Charts of patients who were diagnosed with early glottic cancer between 2006 and 2013 were reviewed.
Seventy-five patients were identified, and split into 2 groups based on their primary treatment, trans-oral laser
microsurgery and radiation therapy. Kaplan–Meier survival curves, life-tables, and the log-rank statistic were
reported to determine if there was a difference between the two treatment groups and their disease-specific survival,
disease-free survival, and total laryngectomy-free survival. Additionally, each different survival analysis was stratified by
potential confounding variables, to help conclude which treatment is more efficacious in this population.
Results: The 5-year disease-specific survival rate is 93.3 % σ = 0.063 and 90.8 % σ = 0.056 for patients treated with
trans-oral laser microsurgery and radiation therapy, respectively (χ2 < 0.001, p = 0.983). The disease free survival
rate is 60.0 % (σ =0.121) for patients treated with trans-oral laser microsurgery, and 67.2 % (σ = 0.074) for those
who received RT (χ2 = 0.19, p = 0.663). Additionally, the total laryngectomy-free survival rate is 84.1 % (σ = 0.1) and
79.1 % (σ = 0.072) for patients’ early glottic cancer treated by trans-oral laser microsurgery and radiation therapy,
respectively (χ2 = 0.235, p = 0.628). Chi-square analysis of age-group versus treatment group (χ2 = 6.455, p = 0.04)
and T-stage versus treatment group (χ2 = 11.3, p = 0.001) revealed a statistically significant relationship, suggesting
survival analysis should be stratified by these variables. However, after stratification, there was no statistically significant
difference between the trans-oral laser microsurgery and radiation therapy groups in any of the survival analyses.
Conclusion: No difference was demonstrated in the 5-year disease-specific survival, disease-free survival, and total
laryngectomy-free survival, between the RT and TLM treatment groups. Additionally, both groups showed similar
5-year survival after stratifying by confounding variables.
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Background
Deaths due to laryngeal cancer have been decreasing at
a rate greater than 4 % each year since 2001 as reported
by the Canadian Cancer Society. However, this figure, as
explained by the Canadian Cancer Society, is largely due
to the reductions in tobacco use rather than improvements
in treatment [1]. Though this statistic is encouraging, more
research is needed to evaluate best practice for larynx can-
cers to further help improve the survival rate of patients
afflicted by these cancers. Standard care for glottic cancers
staged T1 or T2, or early glottic cancer, is still up for
contention. The literature reports various treatment
methodologies, such as trans-oral laser microsurgery
(TLM), radiation therapy (RT), total/partial laryngecto-
mies, and concurrent radiation chemotherapy. How-
ever, at the forefront of early glottis cancer treatment is
TLM and RT, likely due to better functional and survival
outcomes. This study seeks to compare TLM and RT in
early glottic cancer patients treated at Sunnybrook Health
Sciences Centre., by analyzing their 5-year disease-specific
survival, disease-free survival, and total laryngectomy-free
survival.
Though several studies have compared TLM and RT,
there seems to be a lack of consideration of potential
confounding variables, and how they may affect the re-
sults. This report will identify 3 potential variables that
may confound the results, test for their significance in
the dataset, and stratify the analysis based on them if it
proves reasonable. This will help to ensure that the results
are showing what they are intended to, and avoid false
conclusions. Mainly this study seeks to add more current
data to the body of literature as the largest Canadian
head-to-head comparison of consecutive patients treated
with either RT or TLM, in order help make conclusions
about which treatment should be used.
Methods
Patients
Charts of consecutive patients who were diagnosed with
early glottic cancer between 2006 and 2013 were reviewed.
Charts were collated from a list created by Sunnybrook
Heath Science Centre otolaryngology research team by
searching for all glottic cancer patients who were staged
as T1 or T2. Cancer staging was done by pathologists at
Sunnybrook Health Sciences Centre. Patients were only
included in the study if their primary treatment was TLM
or RT. All patients were given the option of either RT and
TLM, and were treated under the care of a multidisciplin-
ary team for head and neck cancer at Sunnybrook Health
Sciences. Eighty-four patients were identified, and evalu-
ated by a single reviewer. Four of the patients were ex-
cluded since their primary treatment did not include
exclusively RT or TLM, 3 were excluded since the primary
treatment was not available in the charts, and 2 were
excluded since their T-stage was not available. This
project was approved by the Research Ethics Board of
Sunnybrook Health Science Centre (206–2009).
Data collection
All data was collected by a single reviewer from the
collated patient charts. Data extracted from the charts
included demographic information, the patients’ initial
treatment, T-stage, length of follow-up, and time until
the patient died of the disease. Time measurements
were calculated starting from the completion of primary
treatment until death, or last follow-up date. Minimum
follow-up was 1-month.
Interventions
All patients in the radiation group were treated with
intensity-modulated radiation therapy (IMRT). All patients
in the surgery group were under the care of the attending
surgeons KH or DE, and were treated with a CO2 laser.
Statistical analysis
Statistical analysis was undertaken using SPSS® (V20,
IBM Corp ©). Statistical significance for all tests were
Table 1 Overall Subject Characteristic
Number of Patients 75




Age Group Distribution <65 : 25
65–75 : 28
>75 : 22
Radiation Dosage for RT group 46 Gy-70 Gy
mean = 54.71 Gy
Table 2 Subject Characteristics Stratified by Treatment Group
TLM RT Statistical
Significance
Age mean = 72.5 mean = 66.5 p = 0.03
Age Group: <65 : 4 <65 : 21 p = 0.04
65–75 : 8 65–75 : 20
>75 : 11 >75 : 11
T Stage T1 = 21 T1 = 26 p = 0.001
T2 = 2 T2 = 26
Smoking Status Non-smoker: 7 Non-smoker: 5 p = 0.054
Smoker: 16 Smoker: 47
Smoking Pack-Years mean = 20.2 mean = 31.7 p = 0.069
Gender Male: 20 Male: 46 p = 1.00-
Female: 3 Female: 6
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Fig. 1 Overall 5-year survival curve. This survival curve depicts the 5-year survival for all patients reported in this study. Censored patients are
those whose did not die from the cancer but were lost to follow-up before the 5-year mark
Fig. 2 Distribution of patients by treatment group stratified by T-Stage. This double bar graph represents the distribution of patients who underwent
TLM or RT stratified by their cancer’s T stage. 23 patients were treated with TLM, with 21 patients having a cancer staged as T1 and 2 as T2; and 52
patients were treated with RT, with 26 patients having a cancer staged as T1 and 26 as T2. A statistically significant difference in the distribution
of T-stage across treatment group was observed (χ2 = 11.3, p = 0.001)
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Fig. 3 Distribution of patients by treatment group stratified by age group. This double bar graph represents the distribution of patients who underwent
TLM or RT stratified by their age group. 23 patients were treated with TLM, with 4 less than 65 years old (5.3 %), 8 patients 65–75 years old (10.7 %), and 11
patients greater than 75 years old (14.7 %); and 52 patients were treated with RT, with 21 patients less than 65 years old (28 %), 20 patients 65–75 years old
(26.7 %), and 11 greater than 75 years old (14.7 %). A statistically significant difference in the distribution of age group across treatment group
was observed (χ2 = 6.455, p = 0.04)
Fig. 4 5-year disease-specific survival curve by treatment group. This survival curve depicts the 5-year disease-specific survival for all patients reported in
this study, and is divided by treatment group, TLM and RT. No statistically significant relationship was observed between treatment group and 5-year
survival (χ2 < 0.001, p= 0.983). Censored patients are those whose did not die from their primary cancer but were lost to follow-up before the 5-year mark
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Std. Error of Cumulative
Proportion Surviving at
End of Interval
TLM 0 23 0 23.000 0 1.00 1.00 .00
1 23 1 22.500 0 1.00 1.00 .00
2 22 0 22.000 0 1.00 1.00 .00
3 22 0 22.000 0 1.00 1.00 .00
4 22 0 22.000 0 1.00 1.00 .00
5 22 1 21.500 0 1.00 1.00 .00
6 21 0 21.000 0 1.00 1.00 .00
7 21 1 20.500 0 1.00 1.00 .00
8 20 0 20.000 0 1.00 1.00 .00
9 20 0 20.000 0 1.00 1.00 .00
10 20 1 19.500 0 1.00 1.00 .00
11 19 1 18.500 0 1.00 1.00 .00
12 18 1 17.500 0 1.00 1.00 .00
13 17 0 17.000 0 1.00 1.00 .00
14 17 0 17.000 0 1.00 1.00 .00
15 17 0 17.000 0 1.00 1.00 .00
16 17 0 17.000 0 1.00 1.00 .00
17 17 0 17.000 0 1.00 1.00 .00
18 17 0 17.000 0 1.00 1.00 .00
19 17 0 17.000 0 1.00 1.00 .00
20 17 0 17.000 0 1.00 1.00 .00
21 17 1 16.500 0 1.00 1.00 .00
22 16 0 16.000 0 1.00 1.00 .00
23 16 1 15.500 0 1.00 1.00 .00
24 15 0 15.000 1 .93 .93 .06
25 14 1 13.500 0 1.00 .93 .06
26 13 0 13.000 0 1.00 .93 .06
27 13 1 12.500 0 1.00 .93 .06
28 12 0 12.000 0 1.00 .93 .06
29 12 1 11.500 0 1.00 .93 .06
30 11 0 11.000 0 1.00 .93 .06
31 11 0 11.000 0 1.00 .93 .06
32 11 0 11.000 0 1.00 .93 .06
33 11 0 11.000 0 1.00 .93 .06
34 11 0 11.000 0 1.00 .93 .06
35 11 1 10.500 0 1.00 .93 .06
36 10 0 10.000 0 1.00 .93 .06
37 10 1 9.500 0 1.00 .93 .06
38 9 1 8.500 0 1.00 .93 .06
39 8 0 8.000 0 1.00 .93 .06
40 8 1 7.500 0 1.00 .93 .06
41 7 0 7.000 0 1.00 .93 .06
42 7 0 7.000 0 1.00 .93 .06
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Table 3 5-year disease-specific survival life-table (Continued)
43 7 0 7.000 0 1.00 .93 .06
44 7 1 6.500 0 1.00 .93 .06
45 6 0 6.000 0 1.00 .93 .06
46 6 0 6.000 0 1.00 .93 .06
47 6 0 6.000 0 1.00 .93 .06
48 6 0 6.000 0 1.00 .93 .06
49 6 0 6.000 0 1.00 .93 .06
50 6 0 6.000 0 1.00 .93 .06
51 6 0 6.000 0 1.00 .93 .06
52 6 1 5.500 0 1.00 .93 .06
53 5 0 5.000 0 1.00 .93 .06
54 5 1 4.500 0 1.00 .93 .06
55 4 0 4.000 0 1.00 .93 .06
56 4 0 4.000 0 1.00 .93 .06
57 4 1 3.500 0 1.00 .93 .06
58 3 0 3.000 0 1.00 .93 .06
59 3 0 3.000 0 1.00 .93 .06
60 3 3 1.500 0 1.00 .93 .06
Radiation 0 52 0 52.000 0 1.00 1.00 .00
1 52 0 52.000 0 1.00 1.00 .00
2 52 1 51.500 0 1.00 1.00 .00
3 51 0 51.000 0 1.00 1.00 .00
4 51 0 51.000 0 1.00 1.00 .00
5 51 1 50.500 0 1.00 1.00 .00
6 50 1 49.500 0 1.00 1.00 .00
7 49 1 48.500 0 1.00 1.00 .00
8 48 0 48.000 0 1.00 1.00 .00
9 48 0 48.000 0 1.00 1.00 .00
10 48 0 48.000 1 .98 .98 .02
11 47 1 46.500 1 .98 .96 .03
12 45 2 44.000 0 1.00 .96 .03
13 43 1 42.500 0 1.00 .96 .03
14 42 1 41.500 0 1.00 .96 .03
15 41 0 41.000 0 1.00 .96 .03
16 41 0 41.000 0 1.00 .96 .03
17 41 0 41.000 0 1.00 .96 .03
18 41 3 39.500 0 1.00 .96 .03
19 38 0 38.000 0 1.00 .96 .03
20 38 1 37.500 0 1.00 .96 .03
21 37 1 36.500 0 1.00 .96 .03
22 36 1 35.500 0 1.00 .96 .03
23 35 0 35.000 0 1.00 .96 .03
24 35 1 34.500 0 1.00 .96 .03
25 34 0 34.000 0 1.00 .96 .03
26 34 4 32.000 0 1.00 .96 .03
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set at p < 0.05. Survival analyses were carried out using
the Kaplan–Meier method, and the curves were com-
pared using the log-rank statistic. Survival rates were
obtained by calculating the cumulative proportion of
patients alive at 5 years, accounting for censored data.
Additionally, Life-tables were produced to aid in the
interpretation of the survival curves. Afterwards, age, T-
stage, and gender were tested to see if they were con-
founding variables using the Chi-square statistic. When
comparing age to treatment modality, age was split into
3 groups, below 65, 65–75, and above 75. Age was split
into three groups to allow for the comparison of the two
treatments on the middle-aged (below 65), the “young-
old” (65–75), and the “older-old” (above 75). The age
cut-offs were set to create approximately equal amounts
of patients in each age group. Depending on the results
of the tests for confounding variables, survival analyses
were stratified by the variables proving to be confounders
Table 3 5-year disease-specific survival life-table (Continued)
27 30 0 30.000 0 1.00 .96 .03
28 30 0 30.000 0 1.00 .96 .03
29 30 0 30.000 0 1.00 .96 .03
30 30 0 30.000 0 1.00 .96 .03
31 30 0 30.000 0 1.00 .96 .03
32 30 0 30.000 0 1.00 .96 .03
33 30 1 29.500 0 1.00 .96 .03
34 29 1 28.500 0 1.00 .96 .03
35 28 0 28.000 0 1.00 .96 .03
36 28 0 28.000 0 1.00 .96 .03
37 28 0 28.000 0 1.00 .96 .03
38 28 0 28.000 0 1.00 .96 .03
39 28 2 27.000 0 1.00 .96 .03
40 26 1 25.500 0 1.00 .96 .03
41 25 0 25.000 0 1.00 .96 .03
42 25 0 25.000 0 1.00 .96 .03
43 25 0 25.000 0 1.00 .96 .03
44 25 0 25.000 0 1.00 .96 .03
45 25 0 25.000 0 1.00 .96 .03
46 25 0 25.000 0 1.00 .96 .03
47 25 1 24.500 0 1.00 .96 .03
48 24 1 23.500 0 1.00 .96 .03
49 23 1 22.500 0 1.00 .96 .03
50 22 0 22.000 0 1.00 .96 .03
51 22 0 22.000 0 1.00 .96 .03
52 22 0 22.000 0 1.00 .96 .03
53 22 1 21.500 0 1.00 .96 .03
54 21 1 20.500 0 1.00 .96 .03
55 20 0 20.000 0 1.00 .96 .03
56 20 0 20.000 0 1.00 .96 .03
57 20 0 20.000 0 1.00 .96 .03
58 20 1 19.500 0 1.00 .96 .03
59 19 0 19.000 0 1.00 .96 .03
60 19 18 10.000 1 .90 .86 .09
This life-table shows the proportion of patients who experienced an event each time-interval (1 month). Additionally, the table indicates the amount of patients
who were censored each month by reporting how many patients entered and left each interval
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and subsequently calculated as explained above. The pri-
mary outcomes are disease-specific survival, disease-free
survival, and total laryngectomy-free survival. Survival
time is measured from the completion of treatment until
an event or the end of the 5-year follow-up is reached.
The definition of the event for each of the 3 survival
analyses is reported in the subsection below: Survival
Analyses. Patients’ who did not experience an event
but were lost to follow-up before the 5-year mark
were used in the survival analysis until they were lost
to follow-up, subsequently they were censored.
Demographic data that were continuous variables
(smoking pack-years and age), were analyzed by a T-test
to determine their mean in each treatment group and
how they were distributed between TLM and RT groups.
Smoking status, being a binary variable, was tested for
equal distribution between the groups using chi-square
analysis. Additionally, the mean radiation dosage for the
RT group was reported.
Survival analyses
Three types of survival analyses were conducted to com-
pare the effectiveness of TLM and RT; disease-specific
survival, disease-free survival, and total laryngectomy-
free survival. Disease-specific survival analysis consid-
ered an event as death from the primary cancer.
Disease-free survival analysis was conducted by classify-
ing an event as the recurrence of the primary cancer or
death from the primary cancer. Moreover, total
laryngectomy-free survival was conducted under the as-
sumption that an event occurred if a patient required a
total laryngectomy or died from their primary cancer.
Results
In total 75 patients, 31 % (23/75) treated with TLM and
69 % (52/75) by RT, were examined. Patient characteris-
tics are listed in Tables 1 and 2. The overall 5-year sur-
vival rate, regardless of treatment is 90.8 % σ = 0.05
(Fig. 1). To proceed to survival analysis comparing the
two treatment groups, it is first necessary to determine
whether potential confounding variables are balanced
between the two groups. Thus, 3 variables were tested to
see if a statistically significant relationship existed be-
tween them and the treatment groups, the independent
variable. If one does exist, the uneven distribution of pa-
tients based on the potential confounder could account
Fig. 5 5-year disease-free survival curve by treatment group. This survival curve depicts the 5-year disease-free survival for all patients reported in
this study, and is divided by treatment group, TLM and RT. No statistically significant relationship was observed between treatment group and
5-year survival (χ2 = 0.19, p = 0.663). Censored patients are those whose cancer did not recur nor did they die from their primary cancer but
were lost to follow-up before the 5-year mark
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Std. Error of Cumulative
Proportion Surviving
at End of Interval
TLM 0 23 0 23.000 0 1.00 1.00 .00
1 23 1 22.500 0 1.00 1.00 .00
2 22 0 22.000 0 1.00 1.00 .00
3 22 0 22.000 0 1.00 1.00 .00
4 22 1 21.500 0 1.00 1.00 .00
5 21 0 21.000 0 1.00 1.00 .00
6 21 1 20.500 0 1.00 1.00 .00
7 20 0 20.000 1 .95 .95 .05
8 19 0 19.000 1 .95 .90 .07
9 18 1 17.500 1 .94 .85 .08
10 16 1 15.500 0 1.00 .85 .08
11 15 0 15.000 0 1.00 .85 .08
12 15 0 15.000 1 .93 .79 .09
13 14 0 14.000 0 1.00 .79 .09
14 14 0 14.000 0 1.00 .79 .09
15 14 0 14.000 0 1.00 .79 .09
16 14 0 14.000 0 1.00 .79 .09
17 14 0 14.000 0 1.00 .79 .09
18 14 1 13.500 1 .93 .73 .10
19 12 0 12.000 0 1.00 .73 .10
20 12 0 12.000 0 1.00 .73 .10
21 12 0 12.000 0 1.00 .73 .10
22 12 0 12.000 0 1.00 .73 .10
23 12 1 11.500 1 .91 .67 .11
24 10 0 10.000 0 1.00 .67 .11
25 10 1 9.500 0 1.00 .67 .11
26 9 0 9.000 0 1.00 .67 .11
27 9 0 9.000 0 1.00 .67 .11
28 9 0 9.000 0 1.00 .67 .11
29 9 0 9.000 0 1.00 .67 .11
30 9 0 9.000 0 1.00 .67 .11
31 9 0 9.000 0 1.00 .67 .11
32 9 0 9.000 1 .89 .60 .12
33 8 0 8.000 0 1.00 .60 .12
34 8 0 8.000 0 1.00 .60 .12
35 8 0 8.000 0 1.00 .60 .12
36 8 1 7.500 0 1.00 .60 .12
37 7 0 7.000 0 1.00 .60 .12
38 7 3 5.500 0 1.00 .60 .12
39 4 0 4.000 0 1.00 .60 .12
40 4 0 4.000 0 1.00 .60 .12
41 4 0 4.000 0 1.00 .60 .12
42 4 1 3.500 0 1.00 .60 .12
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Table 4 5-year disease-free survival life-table (Continued)
43 3 0 3.000 0 1.00 .60 .12
44 3 0 3.000 0 1.00 .60 .12
45 3 0 3.000 0 1.00 .60 .12
46 3 0 3.000 0 1.00 .60 .12
47 3 0 3.000 0 1.00 .60 .12
48 3 0 3.000 0 1.00 .60 .12
49 3 0 3.000 0 1.00 .60 .12
50 3 0 3.000 0 1.00 .60 .12
51 3 1 2.500 0 1.00 .60 .12
52 2 0 2.000 0 1.00 .60 .12
53 2 0 2.000 0 1.00 .60 .12
54 2 0 2.000 0 1.00 .60 .12
55 2 1 1.500 0 1.00 .60 .12
56 1 0 1.000 0 1.00 .60 .12
57 1 0 1.000 0 1.00 .60 .12
58 1 0 1.000 0 1.00 .60 .12
59 1 0 1.000 0 1.00 .60 .12
60 1 1 .500 0 1.00 .60 .12
Radiation 0 52 1 51.500 1 .98 .98 .02
1 50 0 50.000 0 1.00 .98 .02
2 50 1 49.500 1 .98 .96 .03
3 48 0 48.000 0 1.00 .96 .03
4 48 1 47.500 1 .98 .94 .03
5 46 0 46.000 0 1.00 .94 .03
6 46 0 46.000 0 1.00 .94 .03
7 46 0 46.000 2 .96 .90 .04
8 44 1 43.500 0 1.00 .90 .04
9 43 2 42.000 0 1.00 .90 .04
10 41 0 41.000 2 .95 .86 .05
11 39 1 38.500 0 1.00 .86 .05
12 38 0 38.000 1 .97 .83 .05
13 37 0 37.000 1 .97 .81 .06
14 36 0 36.000 1 .97 .79 .06
15 35 0 35.000 0 1.00 .79 .06
16 35 3 33.500 0 1.00 .79 .06
17 32 0 32.000 0 1.00 .79 .06
18 32 0 32.000 1 .97 .76 .06
19 31 0 31.000 0 1.00 .76 .06
20 31 1 30.500 0 1.00 .76 .06
21 30 1 29.500 0 1.00 .76 .06
22 29 2 28.000 0 1.00 .76 .06
23 27 2 26.000 0 1.00 .76 .06
24 25 0 25.000 0 1.00 .76 .06
25 25 0 25.000 0 1.00 .76 .06
26 25 0 25.000 0 1.00 .76 .06
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for the observed results for 5-year survival of patients
with early larynx cancer. However, before stratifying,
there needs to be a reasonable explanation of why that
variable can affect the outcome. Both of these criteria
must be met in order to stratify by a variable in the sur-
vival analysis.
The extent of one’s cancer, often represented by T-stage
can affect the survival of a patient, with more severe can-
cers often having a worse prognosis. When comparing T-
stage to the treatment groups, TLM and RT, through a
Chi-square analysis, a statistically significant relationship
(χ2 = 11.3, p = 0.001) was observed, therefore making it ne-
cessary to stratify based on T stage (Fig. 2). Furthermore, in
general, being older is associated with worse cancer survival
rates, likely due to an overall better general health and re-
sponse to treatments in younger patients [2]. Chi-square
analysis of age-group versus treatment group revealed a sta-
tistically significant relationship (χ2 = 6.455, p = 0.04), thus
making it reasonable to account for age as a confounder
(Fig. 3). Additionally, gender could potentially alter the
Table 4 5-year disease-free survival life-table (Continued)
27 25 0 25.000 0 1.00 .76 .06
28 25 0 25.000 0 1.00 .76 .06
29 25 0 25.000 0 1.00 .76 .06
30 25 0 25.000 0 1.00 .76 .06
31 25 0 25.000 1 .96 .73 .07
32 24 0 24.000 1 .96 .70 .07
33 23 0 23.000 1 .96 .67 .07
34 22 0 22.000 0 1.00 .67 .07
35 22 0 22.000 0 1.00 .67 .07
36 22 1 21.500 0 1.00 .67 .07
37 21 0 21.000 0 1.00 .67 .07
38 21 1 20.500 0 1.00 .67 .07
39 20 0 20.000 0 1.00 .67 .07
40 20 0 20.000 0 1.00 .67 .07
41 20 0 20.000 0 1.00 .67 .07
42 20 1 19.500 0 1.00 .67 .07
43 19 0 19.000 0 1.00 .67 .07
44 19 0 19.000 0 1.00 .67 .07
45 19 0 19.000 0 1.00 .67 .07
46 19 2 18.000 0 1.00 .67 .07
47 17 1 16.500 0 1.00 .67 .07
48 16 0 16.000 0 1.00 .67 .07
49 16 1 15.500 0 1.00 .67 .07
50 15 0 15.000 0 1.00 .67 .07
51 15 0 15.000 0 1.00 .67 .07
52 15 2 14.000 0 1.00 .67 .07
53 13 1 12.500 0 1.00 .67 .07
54 12 0 12.000 0 1.00 .67 .07
55 12 0 12.000 0 1.00 .67 .07
56 12 0 12.000 0 1.00 .67 .07
57 12 1 11.500 0 1.00 .67 .07
58 11 1 10.500 0 1.00 .67 .07
59 10 0 10.000 0 1.00 .67 .07
60 10 10 5.000 0 1.00 .67 .07
This life-table shows the proportion of patients who experienced an event each time-interval (1 month). Additionally, the table indicates the amount of patients
who were censored each month by reporting how many patients entered and left each interval
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cancer specific survival rate, with worse results in males [3].
However, no relationship between treatment group and the
distribution of gender was seen (χ2 = 0.034, p = 1.000).
Consequently, subsequent analyses for 5-year survival
was stratified first by T-Stage. However only 2 patients
whose cancer was categorized as T2 were treated with
TLM (Fig. 3). With such a small sample being T2 and
treated with TLM, a non-meaningful comparison would
result from survival analysis stratified by T stage, and
even less useful results if the analysis was further strati-
fied by age group. Thus survival analysis of all patients
in the sample population was conducted stratified by
age-group only and a subgroup analysis of T1 patients
stratified by age was examined so both age and T stage
were accounted for in the analysis.
Disease-specific survival
Disease-specific 5-year survival rate is 93.3 % (σ= 0.064)
and 90.8 % (σ= 0.056) for patients treated with TLM and
RT, respectively (Fig. 4 and Table 3). The difference in
survival between TLM and RT treatment groups was not
statistically significant, χ2 < 0.001, p = 0.983. Additionally,
we tested whether any variables not matched or controlled
for skewed the results.
However, the log-rank statistic, adjusted for age group,
revealed no significant relationship between treatment
group and cancer related 5-year survival rate (χ2 = 0.347,
p = 0.556). Additionally, the 5-year survival curve of T1
patients stratified by age group yielded no statistically
significant relationship between treatment group and
cancer related 5-year survival rate (χ2 = 0.033, p = 0.856).
Disease-free survival
The disease free survival rate is 60.0 % (σ =0.121) for
patients treated with TLM, and 67.2 % (σ = 0.074) for
those who received RT (Fig. 5 and Table 4). This
difference in survival was not statistically significant
(χ2 = 0.19, p = 0.663). The same conclusion can be
drawn from the log-rank statistic for the survival rate
stratified by age-group (χ2 = 0.049, p = 0.824). Add-
itionally, the 5-year disease free survival curve of T1
patients stratified by age group revealed no statisti-
cally significant difference between TLM and RT
groups (χ2 = 1.034, p = 0.596).
Fig. 6 5-year total laryngectomy-free survival curve by treatment group. This survival curve depicts the 5-year total laryngectomy-free survival for
all patients reported in this study, and is divided by treatment group, TLM and RT. No statistically significant relationship was observed between
treatment group and 5-year survival (χ2 = 0.289, p = 0.591). Censored patients are those whose did not receive a total laryngectomy, nor did they
die from their primary cancer, but were lost to follow-up before the 5-year mark
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Std. Error of Cumulative
Proportion Surviving
at End of Interval
TLM 0 23 0 23.000 0 1.00 1.00 .00
1 23 1 22.500 0 1.00 1.00 .00
2 22 0 22.000 0 1.00 1.00 .00
3 22 0 22.000 0 1.00 1.00 .00
4 22 0 22.000 0 1.00 1.00 .00
5 22 1 21.500 0 1.00 1.00 .00
6 21 0 21.000 0 1.00 1.00 .00
7 21 1 20.500 0 1.00 1.00 .00
8 20 0 20.000 0 1.00 1.00 .00
9 20 0 20.000 0 1.00 1.00 .00
10 20 1 19.500 0 1.00 1.00 .00
11 19 1 18.500 0 1.00 1.00 .00
12 18 1 17.500 0 1.00 1.00 .00
13 17 0 17.000 0 1.00 1.00 .00
14 17 0 17.000 0 1.00 1.00 .00
15 17 0 17.000 0 1.00 1.00 .00
16 17 0 17.000 0 1.00 1.00 .00
17 17 0 17.000 0 1.00 1.00 .00
18 17 0 17.000 0 1.00 1.00 .00
19 17 0 17.000 0 1.00 1.00 .00
20 17 0 17.000 0 1.00 1.00 .00
21 17 1 16.500 0 1.00 1.00 .00
22 16 0 16.000 0 1.00 1.00 .00
23 16 1 15.500 0 1.00 1.00 .00
24 15 0 15.000 1 .93 .93 .06
25 14 1 13.500 0 1.00 .93 .06
26 13 0 13.000 0 1.00 .93 .06
27 13 1 12.500 0 1.00 .93 .06
28 12 0 12.000 0 1.00 .93 .06
29 12 1 11.500 0 1.00 .93 .06
30 11 0 11.000 0 1.00 .93 .06
31 11 0 11.000 0 1.00 .93 .06
32 11 0 11.000 0 1.00 .93 .06
33 11 0 11.000 1 .91 .85 .10
34 10 0 10.000 0 1.00 .85 .10
35 10 1 9.500 0 1.00 .85 .10
36 9 0 9.000 0 1.00 .85 .10
37 9 1 8.500 0 1.00 .85 .10
38 8 1 7.500 0 1.00 .85 .10
39 7 0 7.000 0 1.00 .85 .10
40 7 1 6.500 0 1.00 .85 .10
41 6 0 6.000 0 1.00 .85 .10
42 6 0 6.000 0 1.00 .85 .10
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Table 5 5-year total laryngectomy-free survival life-table (Continued)
43 6 0 6.000 0 1.00 .85 .10
44 6 1 5.500 0 1.00 .85 .10
45 5 0 5.000 0 1.00 .85 .10
46 5 0 5.000 0 1.00 .85 .10
47 5 0 5.000 0 1.00 .85 .10
48 5 0 5.000 0 1.00 .85 .10
49 5 0 5.000 0 1.00 .85 .10
50 5 0 5.000 0 1.00 .85 .10
51 5 0 5.000 0 1.00 .85 .10
52 5 1 4.500 0 1.00 .85 .10
53 4 0 4.000 0 1.00 .85 .10
54 4 1 3.500 0 1.00 .85 .10
55 3 0 3.000 0 1.00 .85 .10
56 3 0 3.000 0 1.00 .85 .10
57 3 1 2.500 0 1.00 .85 .10
58 2 0 2.000 0 1.00 .85 .10
59 2 0 2.000 0 1.00 .85 .10
60 2 2 1.000 0 1.00 .85 .10
Radiation 0 52 0 52.000 0 1.00 1.00 .00
1 52 0 52.000 0 1.00 1.00 .00
2 52 1 51.500 0 1.00 1.00 .00
3 51 0 51.000 0 1.00 1.00 .00
4 51 0 51.000 0 1.00 1.00 .00
5 51 1 50.500 1 .98 .98 .02
6 49 1 48.500 0 1.00 .98 .02
7 48 0 48.000 1 .98 .96 .03
8 47 0 47.000 0 1.00 .96 .03
9 47 0 47.000 1 .98 .94 .03
10 46 1 45.500 1 .98 .92 .04
11 44 1 43.500 1 .98 .90 .04
12 42 1 41.500 0 1.00 .90 .04
13 41 0 41.000 1 .98 .88 .05
14 40 1 39.500 0 1.00 .88 .05
15 39 0 39.000 0 1.00 .88 .05
16 39 0 39.000 0 1.00 .88 .05
17 39 0 39.000 0 1.00 .88 .05
18 39 3 37.500 0 1.00 .88 .05
19 36 0 36.000 0 1.00 .88 .05
20 36 1 35.500 0 1.00 .88 .05
21 35 1 34.500 0 1.00 .88 .05
22 34 1 33.500 0 1.00 .88 .05
23 33 0 33.000 0 1.00 .88 .05
24 33 1 32.500 0 1.00 .88 .05
25 32 0 32.000 0 1.00 .88 .05
26 32 3 30.500 0 1.00 .88 .05
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Total laryngectomy-free survival
The total laryngectomy-free survival rate is 84.1 % (σ = 0.1)
and 79.1 % (σ = 0.072) for patients’ early glottic cancer
treated by TLM and RT, respectively (Fig. 6 and Table 5).
This variation in the survival rates was not statistically
significant (χ2 = 0.289, p = 0.591). Furthermore, upon
stratifying by age, log-rank statistics reveal no significant
difference in the survival rates (χ2 = 0.235, p = 0.628). This
conclusion is congruent to the results of the laryngectomy
free survival analysis of T1 patients stratified by age-group
(χ2 = 1.692, p = 0.429).
Discussion
An analysis of early glottic cancer patients at Sunny-
brook did not demonstrate a difference in the 5-year
disease-specific survival, disease-free survival, and total
laryngectomy-free survival, between the RT and TLM
groups. Though these results clash with those reported
Table 5 5-year total laryngectomy-free survival life-table (Continued)
27 29 0 29.000 0 1.00 .88 .05
28 29 0 29.000 0 1.00 .88 .05
29 29 0 29.000 0 1.00 .88 .05
30 29 0 29.000 0 1.00 .88 .05
31 29 0 29.000 0 1.00 .88 .05
32 29 0 29.000 0 1.00 .88 .05
33 29 1 28.500 0 1.00 .88 .05
34 28 1 27.500 0 1.00 .88 .05
35 27 0 27.000 0 1.00 .88 .05
36 27 0 27.000 0 1.00 .88 .05
37 27 0 27.000 0 1.00 .88 .05
38 27 0 27.000 0 1.00 .88 .05
39 27 2 26.000 0 1.00 .88 .05
40 25 1 24.500 0 1.00 .88 .05
41 24 0 24.000 0 1.00 .88 .05
42 24 0 24.000 0 1.00 .88 .05
43 24 0 24.000 0 1.00 .88 .05
44 24 0 24.000 0 1.00 .88 .05
45 24 0 24.000 0 1.00 .88 .05
46 24 0 24.000 0 1.00 .88 .05
47 24 1 23.500 0 1.00 .88 .05
48 23 1 22.500 0 1.00 .88 .05
49 22 1 21.500 0 1.00 .88 .05
50 21 0 21.000 0 1.00 .88 .05
51 21 0 21.000 1 .95 .83 .06
52 20 0 20.000 0 1.00 .83 .06
53 20 1 19.500 0 1.00 .83 .06
54 19 0 19.000 1 .95 .79 .07
55 18 0 18.000 0 1.00 .79 .07
56 18 0 18.000 0 1.00 .79 .07
57 18 0 18.000 0 1.00 .79 .07
58 18 1 17.500 0 1.00 .79 .07
59 17 0 17.000 0 1.00 .79 .07
60 17 17 8.500 0 1.00 .79 .07
This life-table shows the proportion of patients who experienced an event each time-interval (1 month). Additionally, the table indicates the amount of patients
who were censored each month by reporting how many patients entered and left each interval
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by Hartl et al (2012) and van Gogh et al (2012), they are
consistent with a systematic review by Loon et al (2012)
and meta-analysis by Higgins (2011), and retrospective co-
hort study by Remmelts et al (2012) [4–7]. The litera-
ture reports 5-year survival rates ranging from 75 to
93 % [4, 7–16], which is consistent with the results re-
ported in this paper [4, 7–16].
The consideration of confounding variables was impera-
tive to this study, especially as very few studies consider the
potential effects various T stages, age and gender can have
on the data. Thus to avoid skewed results, variables were
tested to see if they had some relationship with the treat-
ment groups to allow for stratification and more accurate
results. Though no significant relationship was found be-
tween treatment modality and survival even after stratifica-
tion, accounting for confounding variables helped to ensure
the verity of the results.
The results of this study add to the existing literature that
suggests TLM and RT are both effective treatment modal-
ities for early larynx cancer, and provide similar results in
terms of preventing cancer related deaths. This result is
important as it can help in the decision process of making
recommendations for patients’ treatment plans. One factor
in choosing which treatments should be used is the cost.
Since the literature tends to agree that neither treatment
produces better oncologic [6–8, 17] or functional out-
comes [7, 9, 10, 18, 19] making decision based on cost
is reasonable.
A meta-analysis by Higgins (2011) shows that in Ontario,
TLM is more cost-effective when compared to RT [7]. It is
suggested that is largely due to TLM having more afford-
able options for salvage treatment in comparison to RT [7].
These results were also supported by a Chinese meta-
analysis suggesting that TLM is significantly cheaper than
RT in the context of early glottis cancer. Furthermore, they
conclude that TLM should be used over RT due the drastic
difference in prices [9]. Merrot et al. (2010) also indicate
similar conclusions based on a meta-analysis of French
healthcare facilities [10]. These studies provide a good
indication of which treatment is more cost-effective,
and the fact that three meta-analyses from different
regions suggest similar results, is encouraging. However, it
could be dangerous to apply the conclusions of these
studies to different jurisdictions. Thus, it is encour-
aged for other healthcare networks to conduct similar
reviews to help decision makers in their respective
dominions.
Limitations of this study are intrinsically linked to
its retrospective nature. Radiation dosage were not
standardized or controlled for. Furthermore, patients
were not randomized into their treatment group. Thus
the effectiveness of each treatment may be skewed as
a patient’s treatment was selected since it was thought
by the patient and the clinical team that it would yield
better results for that patient. As well patients’ comor-
bidities could have affected their survival and treat-
ment selection. However, ethically, it may be difficult
to conduct a perfect randomized study, since a certain
treatment for a specific patient may go against the
clinician’s and patient’s beliefs about what the best
treatment is. Moreover, there was an imbalance of pa-
tients in each treatment group. This variance could
have affected the observed results. However, prevent-
ive measures were in place to minimize such an effect
by stratifying the results and conducting subgroup
analysis. Additionally, the results only reflect a single
institution experience, thus making the results dependent
on the clinician’s individual expertise. Thus, multi-
institutional studies or meta-analyses are necessary to
make more established conclusions.
Conclusion
No difference was demonstrated in the 5-year disease-
specific survival, disease-free survival, and total
laryngectomy-free survival, between the RT and TLM
treatment groups. Additionally, both groups showed
similar 5-year survival before and after stratifying by
confounding variables; age and T stage. The signifi-
cance of this result, when combined with the existing
evidence in the literature, is that decisions on which
treatment should be prescribed may not need to be
centered around efficacy, but rather on other meaningful
factors such as voice quality, patient values, or cost. Des-
pite being limited by the retrospective study design, this
study is the largest Canadian comparison of consecutive
patients treated with either RT or TLM, and stands out
for considering potential confounders as means for ensur-
ing the validity of the results.
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